Effects of added PGX®, a novel functional fibre, on the glycaemic index of starchy foods.
The development of lower-glycaemic index (GI) foods requires simple, palatable and healthy strategies. The objective of the present study was to determine the most effective dose of a novel viscous fibre supplement (PGX®) to be added to starchy foods to reduce their GI. Healthy subjects (n 10) consumed glucose sugar (50 g in water × 3) and six starchy foods with a range of GI values (52-72) along with 0 (inert fibre), 2.5 or 5 g granular PGX® dissolved in 250 ml water. GI testing according to ISO Standard 26,642-2010 was used to determine the reduction in GI. PGX® significantly reduced the GI of all six foods (P < 0.001), with an average reduction of 19 % for the 2.5 g dose and 30 % for the 5 g dose, equivalent to a reducing the GI by 7 and 15 units, respectively. Consuming small quantities of the novel functional fibre PGX®, mixed with water at the start of a meal, is an effective strategy to reduce the GI of common foods.
Boden Institute of Obesity, Nutrition and Exercise, School of Molecular Bioscience, University of Sydney, Sydney, NSW 2006, Australia. jennie.brandmiller@sydney.edu.au
Jennie C
JC
Brand-Miller
Fiona S
FS
Atkinson
Roland J
RJ
Gahler
Veronica
V
Kacinik
Michael R
MR
Lyon
Simon
S
Wood
D000328:Adult; D000464:Alginates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose; D001939:Bread / Q000009:adverse effects; D018592:Cross-Over Studies; D004032:Diet / Q000009:adverse effects; D004040:Dietary Carbohydrates / Q000009:adverse effects; D004043:Dietary Fiber / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019587:Dietary Supplements / Q000009:adverse effects; D004338:Drug Combinations; D057140:Fast Foods / Q000009:adverse effects; D005260:Female; D038321:Glycemic Index; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000517:prevention & control*; D008297:Male; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019518:Postprandial Period; D013213:Starch / Q000009:adverse effects; D014783:Viscosity; D055815:Young Adult
D000464:Alginates; D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004043:Dietary Fiber; D004338:Drug Combinations; C540519:PolyGlycoplex; D011135:Polysaccharides, Bacterial; D013213:Starch